Stifel reiterates Heartflow stock rating on clinical data strength By Investing.com

Heartflow reported Q4 FY2025 EPS of -$0.12 vs -$0.15 consensus and revenue of $49.1M vs $46.6M consensus (+40% YoY). LTM revenue is $176M (+40%) with a 77% gross margin, though the company remains unprofitable and currently trades at $24.83 below analyst targets of $35–$43. Multiple analysts responded positively (Stifel Buy $40 PT; Piper Sandler Overweight $38 PT; Canaccord raised PT to $43) and management reiterated confidence in a 2026 plaque-revenue ramp and large underpenetrated CCTA market, supporting further upside.

Analysis

HeartFlow’s core commercial lever is workflow penetration inside health systems rather than one-off sales; that makes radiology and cardiology procurement cycles the true pacing item. Expect meaningful revenue inflection only after 12–24 month wins with integrated EMR/PACS deployments and payer coverage updates—short-term quarterly beats can mislead on durable adoption.

Second-order beneficiaries include CT OEMs and cloud/compute providers because incremental CCTA volume lifts CT utilization and recurring processing revenue; imaging service consolidators (outpatient radiology chains) also gain negotiating leverage. Conversely, cath‑lab consumable vendors and FFR device makers face gradual demand erosion in elective diagnostic pathways, though cath labs retain procedural revenue from therapeutic interventions.

Key risks center on reimbursement cadence, regulatory/IP entanglements, and commoditization by incumbent imaging vendors or open-source AI models; each could compress margins or shorten pricing power. Watch three catalysts on 3–18 month horizons—major payer policy changes, a banner systemwide roll‑out announcement, or an adverse patent/legal ruling—that would respectively accelerate, confirm, or derail the bull case.

The bullish narrative today prices multi-year conversion of an underpenetrated installed base; if implementation execution, per‑scan economics, or payer acceptance falter, downside will be material and rapid. Maintain a KPI‑driven posture: monitor net new installed sites, ARPS (average revenue per scan), payer coverage language, and multi-year contracting cadence before scaling exposure.

Key Decisions for Investors

• Initiate a tactical long on HTFL (size 1–1.5% NAV) via a 9–18 month call spread to capture runway from system rollouts while capping premium risk; target 2.5x upside if adoption accelerates post a large-system win, max loss = premium.
• Pair trade: long HTFL (0.8% NAV) / short ABT or BSX (0.8% NAV) to express share shift from invasive FFR to noninvasive CCTA over 12–36 months; scenario R/R: asymmetric upside if HTFL wins share, but cap position size given diversification risk in large medtechs.
• Play the equipment cascade: buy 6–12 month call exposure to GE (GE) to capture incremental CT replacement/upgrades from rising CCTA volume; keep position size small (0.5–1% NAV) due to macro capex sensitivity.
• Event-driven leg: set conditional orders to add HTFL on (a) announced favorable national payer coverage or (b) a multi-hospital system contract — add size incrementally up to 3% NAV; conversely trim to zero on any adverse patent/legal announcement.